Experimental drug appears to slow progression of Alzheimer's disease in clinical trial but raises safety concerns

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association with

Related Keywords

United States ,United Kingdom ,San Francisco ,California ,Edinburgh ,City Of ,America ,Richard Isaacson ,Bart De Strooper ,Alois Alzheimer ,Marwan Sabbagh ,Lynn Kramer ,Christopher Van Dyck ,Warner Bros ,United Science Media Centre ,Centre For Discovery Brain Sciences ,Barrow Neurological Institute ,Drug Administration ,University Of Edinburgh ,United Kingdom Dementia Research Institute ,Discovery Company ,Alzheimer Association ,Cable News Network Inc ,Science Media Centre ,Yale Alzheimer Disease Research Center ,New England Journal ,North America ,Yale Alzheimer ,Disease Research Center ,Clinical Trials On Alzheimer ,Disease Conference ,Biologics License Application ,Weill Cornell Medicine ,Tara Spires Jones ,Discovery Brain Sciences ,United Kingdom Based Science Media ,Science Media ,News Network ,